Hugel resubmits BLA for its botulinum toxin, Botulax to the U.S. FDA
Hugel received CRL from the U.S. FDA last March and completely supplemented documents and data. It is expected to obtain the U.S. FDA's approval in the first half of 2023 and aims to become a TOP 3 botulinum toxin brand in the U.S. market. SEOUL, South Korea, Oct. 7, 2022...
ZEISS Makes Fifth Appearance at CIIE, Placing Great Effort in Localization Strategy
SHANGHAI, Nov. 6, 2022 /PRNewswire/ -- The fifth China International Import Expo (CIIE) is currently under way at National Exhibition and Convention Center. ZEISS, a global leader in optics and optoelectronics, is making its fifth appearance in this year's CIIE, showcasing its products at Booth B4-01 in Hall 4.1 with a theme of "A Heart for Science". Innovative products...
DocDoc to work with Aon and insurers in Asia to offer data-enabled patient empowerment solutions to members of employer health plans
This collaboration will address a growing need among employers for effective cost-containment solutions, which empower their members with the data they need to make impactful healthcare decisions. DocDoc's data-enabled group health insurance solutions are to be offered to Aon's clients across multiple markets in Asia starting with Singapore in October 2022, followed by other markets in the region, in...
RVAC Medicines Secures HSA Approval to Initiate Phase 1B Clinical Trial in Singapore
SINGAPORE, Feb. 21, 2023 /PRNewswire/ -- RVAC Medicines Pte. Ltd. (RVAC), a messenger RNA (mRNA) technology platform company, announced today that it has secured the approval from the Health Sciences Authority (HSA) to initiate Phase 1B clinical trial in Singapore to evaluate the safety and immunogenicity of three COVID-19 mRNA vaccine candidates. The clinical trial aims to evaluate three of RVAC's...
Bolstering Healthcare Quality in Malaysia with Renowned Flagship Hospitals
Malaysia's position as a safe and trusted destination for high-quality healthcare services is reinforced with the debut of flagship medical tourism hospitals in the country. KUALA LUMPUR, Malaysia, March 16, 2023 /PRNewswire/ -- Malaysia has debuted its first-of-its-kind Flagship Medical Tourism Hospital Programme, announcing the four (4) shortlisted finalists for the programme, namely National Heart Institute (Institut Jantung Negara),...
OBiO and CHINAGENE reached a strategic agreement of commercial manufacturing services for gene therapy products
SHANGHAI, April 29, 2023 /PRNewswire/ -- On April 21, 2023, OBiO Technology (Shanghai) Corp., Ltd. (OBiO) announced a strategic agreement of commercial manufacturing collaboration with CHINAGENE. Under the agreement, OBiO will provide holistic contract development and manufacturing services to CHINAGENE for their gene therapy products, including large-scale cGMP manufacturing service for clinical...
SNIPR Biome’s data on first clinical drug candidate to prevent infections in hematological cancer patients published in Nature Biotechnology
SNIPR001 is a novel CRISPR-Cas therapeutic designed to selectively target antibiotic resistant E. coli, which can cause fatal infections in vulnerable hematological cancer patients SNIPR001 represents the first CRISPR- therapeutic developed to specifically remove E. coli in the human gut In vitro studies showed...
Ascletis Announces China NMPA Approval of Conducting a Phase IIa Clinical Trial for ASC10 to Treat Respiratory Syncytial Virus Infection
--Respiratory syncytial virus (RSV) infection treatment remains huge unmet medical needs and there is no effective drug for treatment globally so far --Dosage of 800 mg ASC10, twice daily was selected to conduct a Phase IIa study in patients with RSV infection --Preclinical research showed that ASC10-A is a potent inhibitor against RSV both in vitro and in...
6-Month Registered Clinical Trial Data on World’s First Transbronchial Pulmonary Radiofrequency Ablation System for Lung Cancer Announced, Showing Significant Efficacy
HANGZHOU, China, Aug. 7, 2023 /PRNewswire/ -- During the Chinese Medical Association 11th National Academic Conference on Respiratory Endoscopy and Interventional Pulmonology on August 5, Broncus (2216.HK) announced postoperative 6-month data of a registered clinical trial on RF II, the world's first transbronchial pulmonary radiofrequency ablation system for lung cancer. The data were reported by Professor Li Shiyue from the...
Inmagene’s OX40 mAb, with an extended half-life and silenced ADCC, enters POC study in Atopic Dermatitis
SAN DIEGO, SHANGHAI and SYDNEY, Aug. 15, 2023 /PRNewswire/ -- Inmagene Biopharmaceuticals ("Inmagene"), a clinical stage biotechnology company developing innovative and differentiated therapies for immunological and inflammatory diseases, announced that the first patient has been dosed in a global multicenter proof-of-concept (POC) study of IMG-007 in adult patients with moderate-to-severe atopic dermatitis (AD). The objective of the study is to...
